Walking Fish Therapeutics, Inc.

8 articles about Walking Fish Therapeutics, Inc.

• Walking Fish Therapeutics Expands Leadership Team

  6/1/2023

  Walking Fish Therapeutics, a leader in B cell engineering, announced the promotion of Julie Kim, PharmD, MS, to Chief Business Officer.

• MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

  5/4/2023

  MaxCyte, Inc. today announced the signing of a strategic platform license (SPL) with Walking Fish Therapeutics , Inc. a biotechnology company that is rapidly advancing B cell-based therapeutics.

• Walking Fish Therapeutics Expands Leadership Team and Debuts New Headquarters as it Advances Its B Cell Therapeutics Towards Clinical Trials

  9/6/2022

  Walking Fish Therapeutics, a leader in B cell engineering, announced it has appointed Georgia Erbez as Chief Operating Officer and moved to a new 22,000 square foot office and world-class laboratory in South San Francisco.

• 

  Money on the Move: February 16–22

  2/23/2022

  More biotech companies turn to private investors as the market churns volatile for life sciences. Here’s who’s scooping up the cash this week.

• Walking Fish Therapeutics Closes $73 Million Series A Financing

  2/16/2022

  Walking Fish Therapeutics , a leader in B cell therapeutics, today announced the completion of an oversubscribed Series A financing, raising a total of $73 million.

• 

  Top Life Sciences Startups to Watch in 2022

  1/6/2022

  BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
• 

  Money on the Move: September 8 – 14

  9/15/2021

  Ramping up after the Labor Day holiday, funds are flowing fast and free into these life science companies.

• Walking Fish Therapeutics Launches with $50 Million in Series A Financing to Accelerate Development of B Cell Therapies for Multiple Diseases

  9/13/2021

  Walking Fish Therapeutics, a leader in B cell engineering, today announced the close of $50M Series A financing— led by investors including Emerson Collective, Illumina Ventures and Quan Capital— to develop B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.